EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP ‐1 Receptor Agonists

Faisal A Al-Harbi iD, Mohanad A Alkuwaiti iD, Yazeed B Alaql, Ahmed K Alsaif, Ahmed A Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A Alnaaim, Sajjad M AlHaddad, Ahmed Y Azzam iD

Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2289-2302

DOI: 10.1002/acn3.70406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 17.04.2026. Verfasst von Faisal A Al-Harbi und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Qassim University, Buraydah, Saudi Arabia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Optic Neuropathy, Ischemic, Pseudotumor Cerebri, Optic Atrophy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged. Hence, this study was designed to examine the relationship between GLP‐1 RA use and optic outcomes in IIH patients.

Methods

This study used the TriNetX Global Collaborative Network to perform a retrospective propensity score‐matched cohort study. It involved GLP‐1 RA exposure status to classify adult patients with IIH. Further, it applied propensity score matching (PSM) on demographics, comorbidities, and medications. In this study, the primary outcome was incident NAION; the secondary outcome was optic atrophy. Cox proportional hazards regression, time‐stratified analyses, and multiple testing corrections were performed.

Results

From 144,678 IIH patients, 15,567 matched pairs were analyzed. GLP‐1 RA use demonstrated significantly decreased NAION risk (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.24–0.93, p = 0.027) and optic atrophy risk (HR 0.78, 95% CI 0.64–0.94, p = 0.009). Time‐stratified analyses have demonstrated protective associations across all evaluated time windows. The optic atrophy finding remained significant after Bonferroni correction, while NAION remained significant after false discovery rate correction. Subgroup analysis revealed stronger protective associations in non‐diabetic patients (risk ratio 0.53, 95% CI 0.41–0.68) compared to diabetic patients (risk ratio 0.76, 95% CI 0.58–0.99).

Conclusions

GLP‐1 RA utilization among IIH patients was associated with a reduced risk of NAION and optic atrophy. These findings align with the proposed pathway linking GLP‐1 RA‐induced weight reduction to lower intracranial pressure and papilledema reduction in IIH patients; residual confounding cannot be ruled out, and prospective studies are needed to confirm these associations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsOptic Neuropathy, IschemicPseudotumor CerebriOptic AtrophyHumansFemaleMaleAdultMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

GLP‐1 receptor agonistsidiopathic intracranial hypertensionnon‐Arteritic anterior ischemic optic neuropathyoptic atrophypseudotumor cerebri

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • College of Medicine, Qassim University, Buraydah, Saudi Arabia.
  • College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • College of Medicine, Al-Rayan Colleges, Al-Madinah, Saudi Arabia.
  • Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Qassim Health Cluster, Qassim, Saudi Arabia.
  • College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.

ORCID-Profile: Faisal A Al-Harbi, Mohanad A Alkuwaiti, Ahmed Y Azzam

Zitieren

APA

Al-Harbi, F. A., Alkuwaiti, M. A., Alaql, Y. B., Alsaif, A. K., Alessa, A. A., Alharbi, M. A., Alfalah, M., Alnaaim, S. A., AlHaddad, S. M., & Azzam, A. Y. (2026). Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP ‐1 Receptor Agonists. Annals of Clinical and Translational Neurology, 13(11), 2289-2302. https://doi.org/10.1002/acn3.70406

Vancouver

Al-Harbi FA, Alkuwaiti MA, Alaql YB, Alsaif AK, Alessa AA, Alharbi MA, et al. Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP ‐1 Receptor Agonists. Annals of Clinical and Translational Neurology. 2026;13(11):2289-2302. doi:10.1002/acn3.70406

BibTeX
@article{AlHarbi2026,
  author = {Al-Harbi, Faisal A and Alkuwaiti, Mohanad A and Alaql, Yazeed B and Alsaif, Ahmed K and Alessa, Ahmed A and Alharbi, Meshari Ayed and Alfalah, Mohammed and Alnaaim, Saud A and AlHaddad, Sajjad M and Azzam, Ahmed Y},
  title = {Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP ‐1 Receptor Agonists},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {11},
  pages = {2289--2302},
  doi = {10.1002/acn3.70406}
}
Kostenlos starten →